NCT03520660 2026-03-11
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
National Institutes of Health Clinical Center (CC)
Phase 4 Active not recruiting
Clinical Trials
13 trialsNCT07298577 2025-12-23
STOPHCC-GAAD
Siriraj Hospital
Phase NA Not yet recruiting
NCT05870969 2023-05-23
dSEARCH
Ruijin Hospital
Recruiting
NCT05376943 2022-05-17
Possible Differences in HCC Course Depending on DAA Treatment
Medical University of Warsaw
Unknown
NCT02785835 2022-03-16
GEHEP-002
Hospital Universitario de Valme
Completed
NCT04460157 2020-07-07
Prediction of Liver-related Outcomes After HCV Cure
Hospital Universitario de Valme
Unknown
NCT03551444 2018-06-11
CAUTIOUS
Ain Shams University
Phase 3 Unknown
NCT02959359 2017-08-07
DAA in the Risk of Recurrence After Curative Treatment of HCC
Taipei Veterans General Hospital, Taiwan
Phase 4 Withdrawn
NCT02771405 2016-05-13
FRI-STC
National Hepatology & Tropical Medicine Research Institute
Phase 3 Unknown
NCT00375661 2015-09-02
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
Kyoto University Hospital
Phase 4 Completed
NCT01831037 2015-01-28
ROLFH
University of Arkansas
Withdrawn
NCT00502086 2011-02-11
Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.
Catalysis SL
Phase 3 Completed
NCT00834860 2010-02-15
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4 Unknown